

ASX Announcement

Results of Annual General Meeting

25 November 2024 – Race Oncology Limited (“Race”) advises that its Annual General Meeting of Shareholders was held today at 12.00 pm AEDT.

The resolutions were voted in accordance with the Notice of Annual General Meeting previously advised to the Australian Securities Exchange.

All resolutions were carried on a poll.

Further information required by section 251AA(2) of the Corporations Act 2001 (Cth) is attached to this announcement.

-ENDS-

About Race Oncology (ASX: RAC)

Race Oncology (ASX: RAC) is an ASX-listed clinical stage biopharmaceutical company with a dedicated mission to be at the heart of cancer care.

Race’s lead asset, bisantrene, is a small molecule chemotherapeutic. Bisantrene has a rich and unique clinical history with demonstrated therapeutic benefits in both adult and paediatric patients, a well- characterised safety profile, and compelling clinical data demonstrating an anticancer effect and less cardiotoxicity over certain anthracyclines, such as doxorubicin.

Race is advancing a reformulated bisantrene (RC220) to address the high unmet needs of patients across multiple oncology indications, with a clinical focus on anthracycline combinations, where we hope to deliver cardioprotection and enhanced anti-cancer activity in solid tumours. Race is also exploring RC220 as a low-intensity treatment for acute myeloid leukaemia.

Race is investigating the effect of bisantrene on the m⁶A RNA pathway, following independent research published by the City of Hope identifying bisantrene as a potent inhibitor of FTO (Fat mass and obesity-associated protein). Dysregulation of the m⁶A RNA pathway has been described in numerous peer reviewed studies as a driver of a diverse range of cancers.

Race Oncology has collaborated with Astex, City of Hope, MD Anderson, Sheba City of Health, UNC School of Medicine, University of Wollongong and University of Newcastle, and is actively exploring partnerships, licence agreements or a commercial merger and acquisition to accelerate access to bisantrene for patients with cancer across the world.

Learn more at www.raceoncology.com.

If you have any questions on this announcement or any past Race Oncology announcements, please go to the Interactive Announcements page in our Investor Hub <https://announcements.raceoncology.com>

Race encourages all investors to go paperless by registering their details with the Company’s share registry, Automic Registry Services, at www.automicgroup.com.au.

Release authorised by:

Pete Smith, Executive Chair
info@raceoncology.com

Media contact:

Jane Lowe +61 411 117 774
jane.lowe@irdepartment.com.au

Disclosure of Proxy Votes

Race Oncology Limited
Annual General Meeting
Monday, 25 November 2024

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

			Proxy Votes				Poll Results (if applicable)			Results
Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 ADOPTION OF REMUNERATION REPORT	P	28,260,556	27,231,855 96.36%	161,624 0.57%	34,714	867,077 3.07%	32,276,722 99.48%	167,451 0.52%	34,714	-
2 ELECTION OF DIRECTOR – DR SERGE SCROFANI	P	45,556,922	44,853,264 98.46%	99,027 0.22%	5,963	604,631 1.33%	49,641,512 99.80%	99,027 0.20%	5,963	Carried
3 RE-ELECTION OF DIRECTOR – DR PETER SMITH	P	45,556,922	44,853,460 98.46%	98,831 0.22%	5,963	604,631 1.33%	49,641,708 99.80%	98,831 0.20%	5,963	Carried
4 ADOPTION OF EMPLOYEE INCENTIVE SECURITIES PLAN	P	26,093,511	25,077,708 96.11%	174,194 0.67%	356,514	841,609 3.23%	30,102,934 99.42%	174,194 0.58%	356,514	Carried
5 ISSUE OF OPTIONS TO DR SERGE SCROFANI	P	45,523,574	44,551,300 97.86%	152,871 0.34%	39,311	819,403 1.80%	49,554,320 99.69%	152,871 0.31%	39,311	Carried

